Indications：Diabetic Wound
GM-XAN005
GM-XAN005 has completed preclinical experiments, demonstrating its efficacy in treating wounds in diabetic rats. It is anticipated that the application for US IND will be submitted in Q4 2024.
**Introduction to Diabetic Wound**
Diabetic wounds are a common complication among individuals with diabetes, with diabetic foot ulcers being the most widely recognized. Due to diabetes-induced neuropathy, patients lack sensation in their feet, making them susceptible to injuries. Additionally, vascular diseases result in tissue hypoxia, hindering wound healing. Elevated blood glucose levels also lead to decreased white blood cell function, creating a conducive environment for bacterial infection in wounds, forming chronic wounds that are challenging to heal.
Currently, antibiotics are the primary drugs used in clinical settings to treat diabetic wounds, aiming to prevent infection. Although there is a protein drug that can accelerate tissue growth, its high cost and perceived limited efficacy contribute to its relatively low market adoption. The diabetic wound healing market still exhibits a substantial demand gap, and with the continuous increase in the number of diabetic patients, the demand for wound healing medications is steadily growing.
